Maha Katabi
SlowingNamed in filings at Sofinnova Venture PartnersOn the current fund
- Board seats filed
- 9
Named in filings at Sofinnova Venture PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Star Therapeutics | Biotech & pharma | September 2025 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, Westlake Biopartners |
| Marea Therapeutics | Biotech & pharma | June 2024 | Third Rock Ventures, Venbio Global Strategic |
| RayzeBio | Biotech & pharma | August 2022 | Venbio Global Strategic, Versant Venture Capital |
| Quanta Therapeutics | Biotech & pharma | October 2021 | Vida Ventures |
| Gyroscope Therapeutics | Biotech & pharma | March 2021 | None on file |
| Vera Therapeutics | Biotech & pharma | October 2020 | Longitude 103.8 East, Longitude Capital, Longitude Prime, Venbio Select, Westlake Biopartners |
| Aerovate Therapeutics | Biotech & pharma | August 2020 | Atlas Venture |
| Apellis Pharmaceuticals | Biotech & pharma | August 2017 | Venbio Global Strategic, Venbio Select |
| EFFECTOR THERAPEUTICS | Biotech & pharma | December 2015 | Abingworth Bioventures, The Column Group, U.S Venture Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Maha Katabi on the board, based on 9 filed seats with a verified or cited source.